Vivos Therapeutics (VVOS) Profit After Tax (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Profit After Tax data on file, last reported at -$7.8 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$7.8 million, down 100.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$25.1 million (down 123.59% YoY), and the FY2025 annual result was -$21.2 million, down 90.99% from the prior year.
• Profit After Tax declined to -$7.8 million in Q1 2026 per VVOS's latest filing, from -$6.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$1.7 million in Q1 2023 and troughed at -$7.8 million in Q1 2026.
• A 5-year average of -$4.6 million and a median of -$5.0 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax soared 68.05% in 2023, then slumped 159.74% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$6.0 million in 2022, then climbed by 28.73% to -$4.3 million in 2023, then soared by 34.52% to -$2.8 million in 2024, then slumped by 146.43% to -$6.9 million in 2025, then slipped by 12.33% to -$7.8 million in 2026.
• Business Quant data shows VVOS's Profit After Tax at -$7.8 million in Q1 2026, -$6.9 million in Q4 2025, and -$5.4 million in Q3 2025.